Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Peptides and method for amplifying CIK cells in vitro

An in vitro amplification and cell technology, applied in the field of chemical biology, can solve problems that cannot meet clinical needs

Active Publication Date: 2020-12-01
范德里希(上海)生物科技有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the content of CD3+CD56+ cells in peripheral blood mononuclear cells (PBMC) is only 1% to 5%, which cannot meet the clinical needs (Gong Zizhen et al., Xanthan gum supports high-density expansion of CIK cells, Chemical Engineering of Colleges and Universities Journal, Volume 33, Issue 1, February 2019)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptides and method for amplifying CIK cells in vitro
  • Peptides and method for amplifying CIK cells in vitro
  • Peptides and method for amplifying CIK cells in vitro

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] 1. Experimental materials

[0018] PBMC human peripheral blood mononuclear cells were purchased from Shenzhen Haodi Huatuo Biotechnology Co., Ltd. and shipped frozen.

[0019] RPMI-1640 culture medium, fetal bovine serum, AIM-V serum-free medium, and human AB serum were purchased from Gibco, USA.

[0020] The amino acid sequences of peptide A and peptide B are as follows, synthesized by conventional solid-phase synthesis method, the N-terminus and C-terminus are not chemically modified, and the purity is ≥98%:

[0021] Peptide A (Sequence NO.1): GRFTMKSEVAQTRPPQ;

[0022] Peptide B (Sequence NO. 2): GRFTKMSEVAQTRPPQ.

[0023] Male healthy SPF grade BALB / c-nu nude mice were purchased from the Institute of Model Animals, Nanjing University, aged 7-8 weeks, weighing 24-26 g.

[0024] 2. Experimental method

[0025] 1. Recovery and passage of PBMC human peripheral blood mononuclear cells

[0026] ①Prepare sterile water at 37 degrees Celsius 5 minutes in advance (prepar...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses peptides and a method for amplifying CIK cells in vitro. Research results of the embodiment of the invention show that a peptide A and a peptide B can effectively promote in-vitro proliferation of CIK cells; meanwhile, technicians in the field know that CD3+CD56+cells are main effector cells of the CIK cells, and the proportion of the CD3+CD56+cells in the cells subjected to induced proliferation of the peptide A and the peptide B is remarkably higher than that of a conventional induced culture method without the peptide A or the peptide B. The high proportion of the CD3+CD56+cells determines that the same number of peptide A and peptide B group cells has stronger tumor lethality in nude mice. Therefore, the peptide A and the peptide B can be used for CIK cell in-vitro amplification to prepare a CIK cell in-vitro amplification reagent.

Description

technical field [0001] The invention belongs to the field of chemical biology and relates to immune cells, in particular to a peptide and a method for expanding CIK cells in vitro. Background technique [0002] Cytokine-induced killer cells (CIK) is a heterogeneous cell population composed of CD3+CD56+ cells, CD3+CD56- cells and a small part of CD3-CD56+ cells. Among them, CD3+CD56+ cells are the main effector cells of CIK cells, and exert their activity of killing tumor cells in a way that is not restricted by the major histocompatibility complex (MHC). Clinical studies have shown that CIK cell-based cell therapy has greatly improved the quality of life, overall survival time and overall survival of patients, which has attracted much attention. However, the content of CD3+CD56+ cells in peripheral blood mononuclear cells (PBMC) is only 1% to 5%, which cannot meet the clinical needs (Gong Zizhen et al., Xanthan gum supports high-density expansion of CIK cells, Chemical Engi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08C12N5/0783
CPCC07K7/08C12N5/0638C12N2501/998
Inventor 单海华
Owner 范德里希(上海)生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com